Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 4,660 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Therapy Clear all
Completed Phase 2 Interventional Results available

A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis

NCT02688647
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Belumosudil, BSC
Drug · Other
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 20, 2026, 5:53 AM EDT
Completed No phase listed Observational

Parental Perception of COVID-19 Vaccine in Technology Dependent Patients

NCT05084976
View directory record Official record
Conditions
Chronic Respiratory Failure, Tracheostomy Complication, Mechanical Ventilation Complication
Interventions
COVID 19 vaccine counseling
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
Up to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 20, 2026, 5:53 AM EDT
Withdrawn Not applicable Interventional

Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung Cancer

NCT02250378
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
Interventions
stereotactic radiosurgery, therapeutic conventional surgery, laboratory biomarker analysis, quality-of-life assessment
Radiation · Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2015 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Not applicable Interventional Results available

Transcranial Direct Current Stimulation (tDCS) for Post COVID-19 Fatigue

NCT04876417
View directory record Official record
Conditions
Post Covid-19 Patients
Interventions
Transcranial Direct Current Stimulation, Sham Transcranial Direct Current Stimulation
Device
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 20, 2026, 5:53 AM EDT
Terminated Not applicable Interventional

PAL to Improve Oral Feeding for Infants With Chronic Lung Disease

NCT05446389
View directory record Official record
Conditions
Chronic Lung Disease of Prematurity, Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia, Preterm Birth
Interventions
Pacifier Activated Lullaby ®
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
1 Day to 33 Weeks
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Not applicable Interventional

High Omega-3/Low Omega-6 Treatment Diet for Aspirin-exacerbated Respiratory Disease (AERD)

NCT02064738
View directory record Official record
Conditions
ASA Triad, Asthma, Nasal Polyps, And Aspirin Intolerance
Interventions
Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Not applicable Interventional Results available

COPD Assessment and Management Bundle Versus Usual Care

NCT01833026
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Spirometry test, Levalbuterol
Device · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 20, 2026, 5:53 AM EDT
Active, not recruiting No phase listed Observational

MYLUNG Consortium Study Protocol 2

NCT05644808
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Not listed
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Daphne, Alabama • Denver, Colorado • Pensacola, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 20, 2026, 5:53 AM EDT
Recruiting Phase 1 Interventional

Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

NCT07660055
View directory record Official record
Conditions
Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer
Interventions
[68Ga]Ga-DWJ155, [177Lu]Lu-DWJ155
Diagnostic Test · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 20, 2026, 5:53 AM EDT
Recruiting Not applicable Interventional

Telehealth for Sleep Apnea: Effectiveness, Implementation, and Cost in the Military Health System

NCT07121452
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
Sleep Navigator
Behavioral
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 64 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Not applicable Interventional

A Pilot Randomized Controlled Trial: CoINTEGRATE

NCT05732285
View directory record Official record
Conditions
Neurocognitive Disorders, Cognitive Dysfunction, Traumatic Brain Injury, Multiple Sclerosis, Mild Cognitive Impairment
Interventions
CRT, CBT, Modifiable lifestyle factors, Usual care Psychoeducation
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.

NCT00603278
View directory record Official record
Conditions
Asthma
Interventions
GW685698X, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
95
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Not applicable Interventional

Perfusion-Induced Hyperthermia for Metastatic Carcinoma

NCT02409108
View directory record Official record
Conditions
Metastatic Non-Small Cell Lung Carcinoma, Solid Tumor, Adult
Interventions
Exatherm-TBH system
Device
Lead sponsor
Jonathan Kiev
Other
Eligibility
22 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 20, 2026, 5:53 AM EDT
Withdrawn Phase 3 Interventional

Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose

NCT06408714
View directory record Official record
Conditions
Opioid Overdose, Opiate Overdose
Interventions
Nalmefene Injection, Naloxone Injection
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 20, 2026, 5:53 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
Dato-DXd, Osimertinib, Pemetrexed, Carboplatin, Cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Fayetteville, Arkansas • Fountain Valley, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD

NCT02347761
View directory record Official record
Conditions
COPD
Interventions
SUN-101 50 mcg BID eFlow (CS) nebulizer, SUN-101 25 mcg BID eFlow (CS) nebulizer, Placebo BID eFlow Closed System (CS) nebulizer
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
44
States / cities
Anniston, Alabama • Phoenix, Arizona • Tempe, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 20, 2026, 5:53 AM EDT
Recruiting Early Phase 1 Interventional

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

NCT05620342
View directory record Official record
Conditions
Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
Interventions
iC9.GD2.CAR.IL-15 T Infusion
Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 20, 2026, 5:53 AM EDT
Recruiting Phase 1 Interventional

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

NCT07216105
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
FT836, Cetuximab, Trastuzumab
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

NCT01211483
View directory record Official record
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
U3-1287, Erlotinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
14
States / cities
Glendale, Arizona • Scottsdale, Arizona • Anaheim, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging

NCT01174056
View directory record Official record
Conditions
Lung Inflammation
Interventions
Zileuton, Pioglitazone placebo, Zileuton placebo, Pioglitazone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years to 44 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

NCT01928576
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Epigenetic Therapy
Interventions
Azacitidine, Entinostat, Nivolumab, CC-486 300
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00124618
View directory record Official record
Conditions
Lung Cancer
Interventions
cetuximab, radiation therapy
Biological · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
175
States / cities
Scottsdale, Arizona • Hollywood, Florida • Jacksonville, Florida + 107 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Phase 3 Interventional

Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00003279
View directory record Official record
Conditions
Lung Cancer
Interventions
BCG vaccine, monoclonal antibody BEC2
Biological
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
34
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 20, 2026, 5:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Digital Applications to Monitor Novel Coronavirus Disease and Response in Colombia - Syndromic and Vaccination Surveillance

NCT05764174
View directory record Official record
Conditions
Vaccination Refusal, COVID-19
Interventions
Factual messages, Narrative message, Mixed message
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
2,409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 20, 2026, 5:53 AM EDT